In vitro phenotypic susceptibility of HIV-2 clinical isolates to protease inhibitors:: Amprenavir, atazanavir, lopinavir, and tipranavir

被引：0
|
作者：
Descamps, D.
Desbois, D.
Damond, F.
Collin, G.
Matheron, S.
Taieb, A.
Peytavin, G.
Bénard, A.
Campa, P.
Chêne, G.
Brun-Vézinet, F.
机构：
[1] Hop Bichat Claude Bernard, F-75877 Paris 18, France
[2] INSERM, U593, Bordeaux, France
[3] Hop St Antoine, F-75571 Paris, France
来源：
ANTIVIRAL THERAPY | 2006年 / 11卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [1] In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors
    Visseaux, Benoit
    Charpentier, Charlotte
    Hurtado-Nedelec, Margarita
    Storto, Alexandre
    Antoine, Romain
    Peytavin, Gilles
    Damond, Florence
    Matheron, Sophie
    Brun-Vezinet, Francoise
    Descamps, Diane
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) : 137 - 139
  • [2] Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors:: raltegravir and evitegravir
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Taieb, A.
    Peytavin, Ct
    Benard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamps, D.
    [J]. ANTIVIRAL THERAPY, 2007, 12 (05) : S92 - S92
  • [3] Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors:: raltegravir and evitegravir
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Taieb, A.
    Peytavin, G.
    Bernard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamp, D.
    [J]. ANTIVIRAL THERAPY, 2007, 12 : S92 - S92
  • [4] HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Peytavin, G.
    Benard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamps, D.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) : 914 - 920
  • [5] Phenotypic susceptibility of HIV-2 clinical isolates to maraviroc
    Visseaux, B.
    Hurtado-Nedelec, M.
    Charpentier, C.
    Antoine, R.
    Storto, A.
    Matheron, S.
    Larrouy, L.
    Damond, F.
    Brun-Vezinet, F.
    Descamps, D.
    [J]. ANTIVIRAL THERAPY, 2011, 16 : A48 - A48
  • [6] In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors
    Back, NKT
    van Wijk, A
    Remmerswaal, D
    van Monfort, M
    Nijhuis, M
    Schuurman, R
    Boucher, CAB
    [J]. AIDS, 2000, 14 (01) : 101 - 102
  • [7] In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors
    Desbois, Delphine
    Roquebert, Benedicte
    Peytavin, Gilles
    Damond, Florence
    Collin, Gilles
    Bernard, Antoine
    Campa, Pauline
    Matheron, Sophie
    Chene, Genevieve
    Brun-Vezinet, Francoise
    Descamps, Diane
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) : 1545 - 1548
  • [8] Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples
    Schnell, T
    Schmidt, B
    Moschik, G
    Thein, C
    Paatz, C
    Korn, K
    Walter, H
    [J]. AIDS, 2003, 17 (08) : 1258 - 1261
  • [9] Analysis of protease inhibitor combinations in vitro:: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates
    Bulgheroni, E
    Citterio, P
    Croce, F
    Lo Cicero, M
    Viganò, O
    Soster, F
    Chou, TC
    Galli, M
    Rusconi, S
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (03) : 464 - 468
  • [10] In vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572
    Charpentier, C.
    Damond, F.
    Collin, G.
    Larrouy, L.
    Matheron, S.
    Chene, G.
    Roquebert, B.
    Nie, T.
    Schinazi, R. F.
    Brun-Vezinet, F.
    Descamps, D.
    [J]. ANTIVIRAL THERAPY, 2010, 15 : A58 - A58
12345